GeneDx Holdings (WGS) Other financing activities (2020 - 2026)

GeneDx Holdings (WGS) has reported Other financing activities for 7 consecutive years, with $97.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Other financing activities rose 13097.01% year-over-year to $97.0 million; the TTM figure through Mar 2026 stood at $98.3 million (up 8036.18% YoY), while the FY2025 annual figure was $2.0 million, up 306.84% from the prior year.
• Other financing activities grew to $97.0 million in Q1 2026 per WGS's latest filing, from $760000.0 in the prior quarter.
• Across five years, Other financing activities topped out at $195.8 million in Q3 2022 and bottomed at -$197.7 million in Q4 2022.
• Historically, Other financing activities has averaged $6.2 million across 5 years, with a median of $598500.0 in 2025.
• On a YoY basis, Other financing activities climbed as much as 20206.78% in 2022 and fell as far as 15651.46% in 2022.
• GeneDx Holdings' Other financing activities stood at -$197.7 million in 2022, then jumped by 99.87% to -$266000.0 in 2023, then tumbled by 5197.74% to -$14.1 million in 2024, then surged by 105.39% to $760000.0 in 2025, then jumped by 12662.89% to $97.0 million in 2026.
• Business Quant data shows WGS's Other financing activities at $97.0 million in Q1 2026, $760000.0 in Q4 2025, and $462000.0 in Q3 2025.